Basel, May 4, 2017 – Novartis announced today that it has notified Conatus Pharmaceuticals Inc., of its exercise of the option to an exclusive license for the global development and commercialization of emricasan, under the option, collaboration and license agreement signed with Conatus on December 19, 2016. The exercise of …
Tag Archives: cirrhosis
May, 2017
August, 2016
-
5 August
Major Treatment Expansion Could Essentially Eliminate Hepatitis C in R.I. by 2030
PROVIDENCE, R.I. [Brown University] — A new Brown University study projects that increasing the number of Rhode Islanders treated every year for hepatitis C virus infection (HCV) to about 2,000 by 2020 would reduce cases by 90 percent and prevent more than 70 percent of expected liver-related deaths in the …
June, 2016
-
28 June
FDA Approves Gilead’s Epclusa as First Pill to Treat All Forms of Hepatitis C
FOSTER CITY, Calif.–(BUSINESS WIRE)–Jun. 28, 2016– Gilead Sciences, Inc.(NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Epclusa® (sofosbuvir 400 mg/velpatasvir 100 mg), the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection. Epclusa …
January, 2016
-
8 January
FDA Grants Priority Review to Expanded Indication for AbbVie’s Viekira Pak
NORTH CHICAGO, Ill., Jan. 7, 2016 /PRNewswire/ — AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) and granted priority review for VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) without ribavirin (RBV) in …
September, 2015
-
2 September
Timely Treatment
When one analyzes the medical records of 1.6 American adults, it turns out there’s a lot to be learned there. Researchers with the Chronic Hepatitis Cohort Study (CHeCS) did just that starting back in 2006 and tracked the ongoing health of those with hepatitis for the next numerous years. As …